BioXcel Therapeutics (BTAI) Invested Capital (2018 - 2026)

BioXcel Therapeutics' Invested Capital history runs 9 years deep, the most recent figure standing at $22.4 million for Q1 2026.

• On a quarterly basis, Invested Capital rose 299.98% year-over-year to $22.4 million in Q1 2026; TTM through Mar 2026 was $75.4 million, a 76.73% decrease from a year earlier, with the FY2025 full-year figure at $24.9 million, down 76.64% from the prior year.
• Invested Capital slipped to $22.4 million in Q1 2026 per BTAI's latest filing, from $24.9 million in the prior quarter.
• Across five years, Invested Capital topped out at $106.7 million in Q4 2024 and bottomed at $56000.0 in Q1 2022.
• The 5-year median for Invested Capital is $101.4 million (2022), against an average of $70.1 million.
• Across the five-year window, Invested Capital surged 184033.93% in 2023 and slumped 94.6% in 2025, its largest moves.
• Year by year, Invested Capital stood at $101.4 million in 2022, then gained by 1.23% to $102.7 million in 2023, then climbed by 3.94% to $106.7 million in 2024, then plunged by 76.64% to $24.9 million in 2025, then decreased by 10.03% to $22.4 million in 2026.
• Per Business Quant, the three latest BTAI Invested Capital figures stand at $22.4 million (Q1 2026), $24.9 million (Q4 2025), and $16.8 million (Q3 2025).